Autres langues I-Mab

Actions

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 24/04/2024			Varia. 5j.	Varia. 1 janv.
1,81 ^USD	+0,56 %		0,00 %	-4,74 %

15/04	I-Mab annonce le changement de son directeur médical	CI
02/04	I-mab Biopharma (Hangzhou) Co. Ltd. a finalisé l'acquisition de I-Mab Biopharma (Shanghai) Co. Ltd. auprès de I-Mab (NasdaqGM:IMAB).	CI

Verastem Names John Hayslip as Chief Medical Officer	18/04
I-Mab Announces Chief Medical Officer Changes	15/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	08/04
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference	05/04
I-Mab Completes Business Divestiture in China	02/04
I-Mab Announces Closing of the Divestiture of Business Operations in China	02/04
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	02/04
I Mab : Resignations of Director and Senior Management - Form 6-K	01/04
I-Mab Announces Executive Resignation	01/04
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	14/03
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	16/02
I-Mab Divests China Operations, Shifts Focus to US Market	09/02
ADRs Close Higher, Renalytix PLC Climbs 96.9%	08/02
I-Mab Signs Agreement to Divest its Assets and Business Operations in China	08/02
Biotech firm I-Mab to divest China operations, shift focus to US	07/02
Biotech firm I-Mab to divest China operations	07/02
I-Mab Announces Board Changes , Effective February 10, 2024	07/02
I-mab Biopharma Co., Ltd. announced that it expects to receive CNY 19 million in funding from I-Mab	07/02
I-Mab Announces Chief Financial Officer Changes	06/02
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading	11/01

Aucun résultat pour cette recherche